Molecular Templates Announces FDA Acceptance of IND Application for MT-6402, a PD-L1-Targeted Engineered Toxin Body Enabled with Proprietary Antigen Seeding Technology

Author's Avatar
Jan 19, 2021
Article's Main Image

Dosing in Phase 1 Study in Subjects with PD-L1-Positive Cancers Expected to Start in 2Q21